Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.34 |
| ▸ | RAB9A | P51151 | 7/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC12A5 | Q9H2X9 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900233 | 0.82 | MAPT (0.35) | RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL21330901 | 0.76 | USP30 (0.46) | USP30 | |
| SCHEMBL21484640 | 0.75 | MEN1 (0.43) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL10015204 | 0.71 | USP30 (0.63) | USP30 | |
| SCHEMBL17142192 | 0.70 | LPL (0.34) | — | |
| SCHEMBL9941920 | 0.70 | LPL (0.34) | — | |
| SCHEMBL9955496 | 0.70 | SLC12A5 (0.49) | NPC1RAB9AKMT2AGRM1MAPT | |
| SCHEMBL17065974 | 0.70 | ALDH1A1 (0.34) | KMT2AMAPTMEN1USP30SMN1; SMN2 | |
| SCHEMBL14718888 | 0.69 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2ALOX15 | |
| SCHEMBL28513510 | 0.69 | CA1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PDK1, PDPK1, PDK3 | NPC1 1230/4885RAB9A 1569/4885KMT2A 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.